PharmaBoardroom

Biosimilar Adoption in the US: Still Lagging Behind Europe

As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…

Chinese Biotech Strategies: Biologics or Small Molecules

While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception…

Aducanumab: On the Regulatory Home Stretch in the USA

In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…

Chinese Biotech Strategies: The Pros & Cons of In-Licensing

Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios…

US Biotech Commercialisation Strategies: How Karyopharm &…

With US still the reigning global champion in biotech innovation, the dynamic and vibrant biopharma ecosystem in the world’s largest healthcare…

Joong Myung Cho – Chairman & CEO, CrystalGenomics,…

Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly…

Michael G. Kauffman – Founder & CEO, Karyopharm…

Karyopharm Therapeutics’ Dr Michael G. Kauffman outlines the genesis of the company he co-founded with his wife, the approval journey of key product…

China Pharma News Roundup September 2020

The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and…

Kerry Blanchard – CEO, Everest Medicines, China

Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist…

Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…

Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…

Biotech Spotlight: Alphamab Oncology, China

Founded in 2009 by CEO Dr XU Ting, Alphamab started its journey as a protein engineering company with the ultimate dream of becoming, as many Chinese…

China Pharma News Roundup August 2020

A roundup of the latest news from Chinese pharma, including Big Pharma players losing out in the latest round of domestic procurement bidding, updates…

Tagged with BIO